Chemistry in the pharmaceutical industry is preferred to be as ‘green’ as possible with the most economical (atom and energy), least wasteful, and safest (chemical and process) processes. In the meantime, disease targets have become more complex. To mitigate these growing challenges, new technologies (e.g., continuous flow, enzymatic chemistry) and new modalities (e.g., antibody-drug conjugates [ADCs)) are being applied more frequently as powerful tools to enable and accelerate drug R&D and manufacturing. In this webinar, we will discuss several cases where we successfully applied flow chemistry (photocatalytic iodination) and enzymes (asymmetric keto reduction) in the synthesis of intermediates of small molecule APIs. We will also discuss an innovative and more sustainable approach to pyrrolobenzodiazepine (PBD) dimer linker-toxins.
Key Learning Objectives:
- Sustainability chemistry goals the pharmaceutical industry
- Key challenges in achieving green chemistry
- Modern technologies that enable greener chemistry
Who Should Attend:
- Pharmaceutical & Fine Chemists
- Academic Chemistry Researchers
- Process & Development Chemists
- Drug Discovery Chemists